Using angiogenic factors to manage gestational hypertension
Use of Angiogenic Factors in the Conservative Management of Gestational Hypertension. Prospective, Randomised, Controlled Study.
This study tests if certain biological markers can help doctors decide the best time to deliver babies for pregnant women with gestational hypertension to keep both mom and baby safe.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Saint Thomas Hospital, Panama Academic / other |
| Locations | 1 site (Panama City, Provincia de Panamá) |
| Trial ID | NCT06123377 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of angiogenic factors in the conservative management of gestational hypertension, a condition that poses risks to both mothers and their babies. By analyzing these factors, the study aims to differentiate between patients who may face complications and those who could benefit from prolonging their pregnancy. The approach focuses on pregnant women diagnosed with gestational hypertension, utilizing specific biomarkers to guide clinical decisions regarding the timing of delivery.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women between 24 and 40 weeks of gestation diagnosed with gestational hypertension and having specific angiogenic factor levels.
Not a fit: Patients with multiple gestations, certain chronic conditions, or those with elevated angiogenic factor levels may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for gestational hypertension, potentially reducing maternal and neonatal complications.
How similar studies have performed: While the use of angiogenic factors in pregnancy management is a developing area, this specific approach to gestational hypertension is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant women between 24 and 40 weeks of gestation. * Diagnosis of Gestational Hypertension based on ACOG criteria * index sFlt-1/PIGF equal or below 33 Exclusion Criteria: * Multiple gestation * Maternal vasculitis * Previous cesarean section (3 or more) * Neurological conditions * Chronic renal disease * Purpura * Heart disease * Index sFlt-1/PIGF of 34 or more
Where this trial is running
Panama City, Provincia de Panamá
- Hospital Santo Tomas — Panama City, Provincia de Panamá, Panama (Recruiting)
Study contacts
- Study coordinator: Osvaldo Reyes, MD
- Email: oreyespanama@yahoo.es
- Phone: +507 65655041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.